کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
11008569 1840444 2018 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse
چکیده انگلیسی
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduces low-density lipoprotein cholesterol levels and improves cardiovascular outcomes. Given the short time frame, these agents have been available for use; reports of nonresponse to the PCSK9 inhibitor therapy are scarce in literature. We describe 2 cases with substantially lesser than expected low-density lipoprotein cholesterol lowering on PCSK9 therapy. Nonresponse to PCSK9 inhibition was attributed to autosomal recessive hypercholesterolemia (secondary to low-density lipoprotein receptor adaptor protein 1 mutation) and plasmapheresis after PCSK9 inhibitor drug injections. Additional PCSK9 inhibitor nonresponders are likely to emerge as the use of these agents increases overtime.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Clinical Lipidology - Volume 12, Issue 5, September–October 2018, Pages 1141-1145
نویسندگان
, , , , , , ,